Show simple item record

dc.contributor.authorParkinson, Craig
dc.contributor.authorScarlett, J A
dc.contributor.authorTrainer, Peter J
dc.date.accessioned2009-08-27T14:18:41Z
dc.date.available2009-08-27T14:18:41Z
dc.date.issued2003-09-26
dc.identifier.citationPegvisomant in the treatment of acromegaly. 2003, 55 (10):1303-14 Adv. Drug Deliv. Rev.en
dc.identifier.issn0169-409X
dc.identifier.pmid14499709
dc.identifier.doi10.1016/S0169-409X(03)00111-X
dc.identifier.urihttp://hdl.handle.net/10541/78905
dc.description.abstractEpidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date.
dc.language.isoenen
dc.subject.meshAcromegaly
dc.subject.meshHuman Growth Hormone
dc.subject.meshHumans
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshReceptors, Somatotropin
dc.titlePegvisomant in the treatment of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hosptial, Wilmslow Road, Manchester M20 4BX, UK.en
dc.identifier.journalAdvanced Drug Delivery Reviewsen
html.description.abstractEpidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date.


Files in this item

This item appears in the following Collection(s)

Show simple item record